<i>HER2</i> Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review
Anti-HER2 therapies have dramatically improved the prognosis of human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. However, the correlation between the <i>HER2</i> copy number and the response rate to anti-HER2 remains unclear. Here, following the PRISMA method, we p...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/4/3590 |
| _version_ | 1797620563884113920 |
|---|---|
| author | Burak Gonullu Eurydice Angeli Frédéric Pamoukdjian Guilhem Bousquet |
| author_facet | Burak Gonullu Eurydice Angeli Frédéric Pamoukdjian Guilhem Bousquet |
| author_sort | Burak Gonullu |
| collection | DOAJ |
| description | Anti-HER2 therapies have dramatically improved the prognosis of human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. However, the correlation between the <i>HER2</i> copy number and the response rate to anti-HER2 remains unclear. Here, following the PRISMA method, we performed a meta-analysis in the neoadjuvant setting in breast cancer to study the association between the <i>HER2</i> amplification level and the pathological complete response (pCR) to anti-HER2 therapies. Nine articles (four clinical trials, five observational studies) were retrieved after full-text screening, involving 11,238 women with locally advanced breast cancer in the neoadjuvant setting. The median <i>HER2/CEP17</i> ratio cut-off value was 5.0 ± 5.0 (min-max = 1.0–14.0). For the overall population, the median pCR rate was 48% using the random effect model. The studies were categorized in quartiles as follows: ≤2 (Class 1); 2.1 to 5.0 (Class 2); 5.1 to 7.0 (Class 3); and >7.0 (Class 4). After grouping, the pCR rates were 33%, 49%, 57%, and 79%, respectively. When we excluded the study by Greenwell et al., which accounted for 90% of the patients, using the same quartiles, we still observed an increasing rate of pCR as the <i>HER2/CEP17</i> ratio increased. This is the first meta-analysis demonstrating the relationship between the <i>HER2</i> amplification level and the percentage of pCR in the neoadjuvant setting among women with HER2-overexpressing breast cancer, with potential therapeutic applications. |
| first_indexed | 2024-03-11T08:43:21Z |
| format | Article |
| id | doaj.art-d056900e59374d1ea814cc541a4b4739 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T08:43:21Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-d056900e59374d1ea814cc541a4b47392023-11-16T21:02:09ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-02-01244359010.3390/ijms24043590<i>HER2</i> Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic ReviewBurak Gonullu0Eurydice Angeli1Frédéric Pamoukdjian2Guilhem Bousquet3Université Paris Cité, INSERM, UMR_S942 MASCOT, 75006 Paris, FranceUniversité Paris Cité, INSERM, UMR_S942 MASCOT, 75006 Paris, FranceUniversité Paris Cité, INSERM, UMR_S942 MASCOT, 75006 Paris, FranceUniversité Paris Cité, INSERM, UMR_S942 MASCOT, 75006 Paris, FranceAnti-HER2 therapies have dramatically improved the prognosis of human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. However, the correlation between the <i>HER2</i> copy number and the response rate to anti-HER2 remains unclear. Here, following the PRISMA method, we performed a meta-analysis in the neoadjuvant setting in breast cancer to study the association between the <i>HER2</i> amplification level and the pathological complete response (pCR) to anti-HER2 therapies. Nine articles (four clinical trials, five observational studies) were retrieved after full-text screening, involving 11,238 women with locally advanced breast cancer in the neoadjuvant setting. The median <i>HER2/CEP17</i> ratio cut-off value was 5.0 ± 5.0 (min-max = 1.0–14.0). For the overall population, the median pCR rate was 48% using the random effect model. The studies were categorized in quartiles as follows: ≤2 (Class 1); 2.1 to 5.0 (Class 2); 5.1 to 7.0 (Class 3); and >7.0 (Class 4). After grouping, the pCR rates were 33%, 49%, 57%, and 79%, respectively. When we excluded the study by Greenwell et al., which accounted for 90% of the patients, using the same quartiles, we still observed an increasing rate of pCR as the <i>HER2/CEP17</i> ratio increased. This is the first meta-analysis demonstrating the relationship between the <i>HER2</i> amplification level and the percentage of pCR in the neoadjuvant setting among women with HER2-overexpressing breast cancer, with potential therapeutic applications.https://www.mdpi.com/1422-0067/24/4/3590<i>HER2</i> amplificationbreast neoplasmspCRneoadjuvant therapyanti-HER2 therapy |
| spellingShingle | Burak Gonullu Eurydice Angeli Frédéric Pamoukdjian Guilhem Bousquet <i>HER2</i> Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review International Journal of Molecular Sciences <i>HER2</i> amplification breast neoplasms pCR neoadjuvant therapy anti-HER2 therapy |
| title | <i>HER2</i> Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review |
| title_full | <i>HER2</i> Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review |
| title_fullStr | <i>HER2</i> Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review |
| title_full_unstemmed | <i>HER2</i> Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review |
| title_short | <i>HER2</i> Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review |
| title_sort | i her2 i amplification level predicts pathological complete response in the neoadjuvant setting of her2 overexpressing breast cancer a meta analysis and systematic review |
| topic | <i>HER2</i> amplification breast neoplasms pCR neoadjuvant therapy anti-HER2 therapy |
| url | https://www.mdpi.com/1422-0067/24/4/3590 |
| work_keys_str_mv | AT burakgonullu iher2iamplificationlevelpredictspathologicalcompleteresponseintheneoadjuvantsettingofher2overexpressingbreastcancerametaanalysisandsystematicreview AT eurydiceangeli iher2iamplificationlevelpredictspathologicalcompleteresponseintheneoadjuvantsettingofher2overexpressingbreastcancerametaanalysisandsystematicreview AT fredericpamoukdjian iher2iamplificationlevelpredictspathologicalcompleteresponseintheneoadjuvantsettingofher2overexpressingbreastcancerametaanalysisandsystematicreview AT guilhembousquet iher2iamplificationlevelpredictspathologicalcompleteresponseintheneoadjuvantsettingofher2overexpressingbreastcancerametaanalysisandsystematicreview |